Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332228 · ClinicalTrials.gov registry record · Phase 2
Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00332228: Completed Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT00332228 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332228, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The overall goal of this research project is to test the efficacy of a newly developed therapy, Behavioral Naltrexone Therapy (BNT), to enhance the success of naltrexone maintenance and long-term abstinence for individuals with heroin dependence. This study includes free detox and outpatient treatment for opioid dependence that includes medication and a behavioral intervention.
Primary Outcome
proportion of patients relapsing to opiate use
Interventions
- DRUG depot naltrexone
- BEHAVIORAL Compliance enhancement (CE)
- DRUG BNT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00332228 record still lists
NCT00332228 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which depot naltrexone is the first listed.
NCT00332228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00332228 about?
NCT00332228 is a clinical study titled "Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence". The overall goal of this research project is to test the efficacy of a newly developed therapy, Behavioral Naltrexone Therapy (BNT), to enhance the success of naltrexone maintenance and long-term abstinence for individuals with heroin dependence. This study includes free detox and outpatient treatme...
What is the current status of trial NCT00332228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2002-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00332228?
The interventions under investigation include: depot naltrexone (DRUG), Compliance enhancement (CE) (BEHAVIORAL), BNT (DRUG).
Who is sponsoring clinical trial NCT00332228?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00332228's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia